← ALNYLAM PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $193.6m | $645.4m | $420.1m | $547.2m | $496.6m | $820.0m | $866.4m | $812.7m | $966.4m | $1.7b | |
| Prepaid Expense and Other Assets, Current | $21.7m | $40.1m | $73.7m | $80.3m | $62.8m | $88.1m | $132.9m | $126.4m | $117.0m | $281.9m | |
| Inventory, Net | — | — | $24.1m | $56.3m | $75.2m | $86.4m | $129.0m | $89.1m | $78.5m | $82.7m | |
| Accounts Receivable, after Allowance for Credit Loss | — | — | — | $14.9m | $33.5m | $73.3m | $32.3m | $99.6m | $102.7m | — | |
| Assets, Current | $671.9m | $1.8b | $1.2b | $1.7b | $2.6b | $2.8b | $2.7b | $3.0b | $3.3b | $4.1b | |
| Property, Plant and Equipment, Net | $114.6m | $181.9m | $320.7m | $425.2m | $465.0m | $502.0m | $523.5m | $526.1m | $502.8m | $513.1m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $221.2m | $241.5m | $231.7m | $215.1m | $199.7m | $191.1m | $194.9m | |
| Other Assets, Noncurrent | $1.6m | $4.2m | $8.6m | $18.1m | $45.0m | $60.2m | $66.1m | $72.0m | $65.3m | $59.5m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | $18.8m | $43.0m | $102.4m | $198.6m | $238.0m | $327.8m | $405.3m | $777.6m | |
| Accrued Liabilities, Current | $42.1m | $72.2m | $112.7m | $197.2m | $355.9m | $395.2m | $545.5m | $713.0m | $887.5m | $1.1b | |
| Assets | $1.3b | $2.0b | $1.6b | $2.4b | $3.4b | $3.6b | $3.5b | $3.8b | $4.2b | $5.0b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $27.7m | $36.9m | $40.5m | $42.0m | $41.5m | $41.9m | $45.5m | |
| Accounts Payable, Current | $54.5m | $28.4m | $59.7m | $49.9m | $52.0m | $73.4m | $98.1m | $55.5m | $88.4m | $115.7m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $276.1m | $293.0m | $281.3m | $261.3m | $243.1m | $229.5m | $225.1m | |
| Deferred Revenue, Current | $33.5m | $41.7m | $3.5m | $77.8m | $127.2m | $149.5m | $42.1m | $102.8m | $55.5m | $4.8m | |
| Deferred Revenue, Noncurrent | $49.4m | $43.1m | $3.5m | $77.8m | $127.2m | $149.5m | $42.1m | $102.8m | $55.5m | $4.8m | |
| Liabilities, Current | $131.7m | $144.3m | $179.5m | $352.6m | $585.3m | $695.7m | $767.9m | $967.8m | $1.2b | $1.5b | |
| Other Liabilities, Noncurrent | $3.1m | $4.3m | $5.0m | $9.3m | $37.9m | $99.0m | $212.6m | $308.4m | $398.1m | $7.6m | |
| Liabilities | $342.6m | $228.3m | $272.8m | $956.4m | $2.4b | $3.1b | $3.7b | $4.1b | $4.2b | $4.2b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $859k | $997k | $1.0m | $1.1m | $1.2m | $1.2m | $1.2m | $1.3m | $1.3m | $1.3m | |
| Retained Earnings (Accumulated Deficit) | ($1.7b) | ($2.1b) | ($2.8b) | ($3.7b) | ($4.6b) | ($5.4b) | ($6.6b) | ($7.0b) | ($7.3b) | ($6.7b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($33.4m) | ($34.4m) | ($33.2m) | ($36.5m) | ($43.6m) | ($33.3m) | ($44.7m) | ($23.4m) | ($34.5m) | ($20.1m) | |
| Additional Paid in Capital, Common Stock | $2.6b | $3.9b | $4.2b | $5.2b | $5.6b | $6.1b | $6.5b | $6.8b | $7.4b | $7.5b | |
| Stockholders' Equity Attributable to Parent | $920.2m | $1.8b | $1.3b | $1.4b | $1.0b | $588.2m | ($158.2m) | ($220.6m) | $67.1m | $789.2m | |
| Liabilities and Equity | $1.3b | $2.0b | $1.6b | $2.4b | $3.4b | $3.6b | $3.5b | $3.8b | $4.2b | $5.0b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.